New search Hide text from Guidelines
B BLOOD AND BLOOD FORMING ORGANSB02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
| The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). |
B02BA Vitamin K
B02BB Fibrinogen
Preparations containing human fibrinogen for systemic use are classified here. B02BB01 is reserved for systemic formulations only.
B02BC Local hemostatics
This group comprises gauze, tampons etc. impregnated with hemostatic agents. Local hemostatics used in dentistry, see A01AD - Other agents for local oral treatment. Epinephrine injection, see C01C - Cardiac stimulants excl. cardiac glycosides. Tissue adhesives, e.g. cyanoacrylate based adhesives, are classified in V03AK. Combinations of e.g. human fibrinogen, aprotinin, thrombin and collagen are classified in B02BC30.
| No DDDs are established for local hemostatics classified in this group. |
B02BD Blood coagulation factors
This group comprises all blood coagulation factors, thrombin etc., incl. preparations for local use, and their combinations. Gene therapy products replacing coagulation factors are also classified in this group.
For systemic formulations of fibrinogen (factor I), see - B02BB - Fibrinogen.
Prothrombin complexes containg three or all four factors are classified in B02BD01 coagulation factor IX, II, VII and X.
Both human derived and recombinant factor VIII and factor IX products will be classified in B02BD02 - coagulation factor VIII and B02BD04 - coagulation factor IX, respectively.
| No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU). |
B02BX Other systemic hemostatics
This group comprises systemic hemostatics, which cannot be classified elsewhere.
| The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia. |
Last updated: 2024-01-26